Gene therapy for the treatment of sensory neuropathy

Expert Opinion on Biological Therapy

Volumn 6, Issue 5, 2006, Pages 499-507

  Mata, Marina ^c   Chattopadhyay, Munmun ^c   Fink, David J ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c NONE

Author keywords

Diabetes; Gene therapy; Herpes simplex virus; Neurotrophins; Polyneuropathy

Indexed keywords

VASCULOTROPIN; VIRUS VECTOR;

GENE THERAPY; GENE TRANSFER; HERPES SIMPLEX VIRUS; HUMAN; NONVIRAL GENE THERAPY; PLASMID; REVIEW; SENSORY NEUROPATHY; SPINAL GANGLION;

ANIMALS; CLINICAL TRIALS; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; GANGLIA, SPINAL; GENE THERAPY; GROWTH SUBSTANCES; HUMANS; MUSCLES; NERVE GROWTH FACTOR; POLYNEUROPATHIES; SIMPLEXVIRUS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ANIMALIA; RODENTIA; SIMPLEXVIRUS;

EID: 33646557701     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.5.499     Document Type: Review

References (92)

1. MARTYN CN, HUGHES RA: Epidemiology of peripheral neuropathy. J. Neurol. Neurosurg. Psychiatry (1997) 62(4):310-318.
2. ENGLAND JD, GRONSETH GS, FRANKLIN G et al.: Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology (2005) 64(2):199-207.
3. DAVIES AM: The role of neurotrophins in the developing nervous system. J. Neurobiol. (1994) 25(11):1334-1348.
4. ECKENSTEIN FP: Fibroblast growth factors in the nervous system. J. Neurobiol. (1994) 25(11):1467-1480.
5. SCHRATZBERGER P, WALTER DH, RITTIG K et al.: Reversal of experimental diabetic neuropathy by VEGF gene transfer. J. Clin. Invest. (2001) 107(9):1083-1092. An outstanding study demonstrating that experimental diabetic neuropathy can be reversed by gene transfer through injection of a plasmid into muscle. This study provides the preclinical evidence that supports the first human trial of gene therapy for neuropathy.
6. BRINES M, CERAMI A: Emerging biological roles for erythropoietin in the nervous system. Nat. Rev. Neurosci. (2005) 6(6):484-494.
7. ERIKSSON NP, LINDSAY RM, ALDSKOGIUS H: BDNF and NT-3 rescue sensory but not motoneurones following axotomy in the neonate. Neuroreport (1994) 5(12):1445-1448.
8. FRIEDMAN B, KLEINFELD D, IP NY et al.: BDNF and NT-4/5 exert neurotrophic influences on injured adult spinal motor neurons. J. Neurosci. (1995) 15(2):1044-1056.
9. MIYATA Y, KASHIHARA Y, HOMMA S, KUNO M: Effects of nerve growth factor on the survival and synaptic function of Ia sensory neurons axotomized in neonatal rats. J. Neurosci. (1986) 6(7):2012-2018.
10. RICH KM, LUSZCZYNSKI JR, OSBORNE PA, JOHNSON EM: Nerve growth factor protects adult sensory neurons from cell death and atrophy caused by nerve injury. J. Neurocytol. (1987) 16(2):261-268.
11. OTTO D, UNSICKER K, GROTHE C: Pharmacological effects of nerve growth factor and fibroblast growth factor applied to the transectioned sciatic nerve on neuron death in adult rat dorsal root ganglia. Neurosci. Lett. (1987) 83(1-2):156-160.
12. VERGE VM, WIESENFELD-HALLIN Z, HOKFELT T: Differential influence of nerve growth factor on neuropeptide expression in vivo: a novel role in peptide suppression in adult sensory neurons. J. Neurosci. (1995) 15(3 Pt 1):2081-2096.
13. DERBY A, ENGLEMAN VW, FRIEDRICH GE et al.: Nerve growth factor facilitates regeneration across nerve gaps: morphological and behavioral studies in rat sciatic nerve. Exp. Neurol. (1993) 119:176-191.
14. CORDEIRO PG, SECKEL BR, LIPTON SA et al.: Acidic fibroblast growth factor enhnaces peripheral nerve regeneration in vivo. Plast. Reconstr. Surg. (1989) 83:1013-1021.
15. ROTH GA, SPADA V, HAMILL K, BORNSTEIN MB: Insulin-like growth Factor I increases myelination and inhibits demyelination in cultured organotypic nerve tissue. Brain Res. Dev. Brain Res. (1995) 88(1):102-108.
16. SCHUMACHER M, JUNG-TESTAS I, ROBEL P, BAULIEU EE: Insulin-like growth factor I: a mitogen for rat Schwann cells in the presence of elevated levels of cyclic AMP. Glia (1993) 8(4):232-240.
17. SVENNINGSEN AF, KANJE M: Insulin and the insulin-like growth factors I and II are mitogenic to cultured rat sciatic nerve segments and stimulate [3H]thymidine incorporation through their respective receptors. Glia (1996) 18(1):68-72.
18. SONDELL M, FEX-SVENNINGSEN A, KANJE M: The insulin-like growth factors I and II stimulate proliferation of different types of Schwann cells. Neuroreport (1997) 8(13):2871-2876.
19. STEWART HJ, BRADKE F, TABERNERO A et al.: Regulation of rat Schwann cell Po expression and DNA synthesis by insulin-like growth factors in vitro. Eur. J. Neurosci. (1996) 8:553-564.
20. CHENG HL, FELDMAN EL: Insulin-like growth factor-I (IGF-I) and IGF binding protein-5 in Schwann cell differentiation. J. Cell. Physiol. (1997) 171(2):161-167.
21. ISHII DN, GLAZNER GW, PU SF: Role of insulin-like growth factors in peripheral nerve regeneration. Pharmacol. Ther. (1994) 62(1-2):125-144.
22. KONINGS PN, MAKKINK WK, VAN DELFT AM, RUIGT GS: Reversal by NGF of cytostatic drug-induced reducton of neurite outgrowth in rat dorsal root ganglia in vitro. Brain Res. (1994) 640(1-2):195-204.
23. HAYAKAWA K, SOBUE G, ITOH T, MITSUMA T: Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and taxol, on adult rat sympathetic ganglion explants in vitro. Life Sci. (1994) 55(7):519-525.
24. WINDEBANK AJ, SMITH AG, RUSSELL JW: The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro. Neurology (1994) 44(3 Pt 1):488-494.
25. APFEL SC, AREZZO JC, LIPSON L, KESSLER JA: Nerve growth factor prevents experimental cisplatin neuropathy. Ann. Neurol. (1992) 31(1):76-80.
26. GAO WQ, DYBDAL N, SHINSKY N et al.: Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann. Neurol. (1995) 38:30-37.
27. HELGREN ME, CLIFFER KD, TORRENTO K et al.: Neurotrophin-3 administration attenuates deficits of pyridoxine-induced large-fiber sensory neuropathy. J. Neurosci. (1997) 17(1):372-382.
28. APFEL SC, AREZZO JC, BROWNLEE M, FEDEROFF H, KESSLER JA: Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res. (1994) 634(1):7-12.
29. DIEMEL LT, BREWSTER WJ, FERNYHOUGH P, TOMLINSON DR: Expression of neuropeptides in experimental diabetes; effects of treatment with nerve growth factor or brain-derived neurotrophic factor. Brain Res. (1994) 21(1-2):171-175.
30. ISHII DN, LUPIEN SB: Insulin-like growth factors protect against diabetic neuropathy: effects on sensory nerve regeneration in rats. J. Neurosci. Res. (1995) 40(1):138-144.
31. ZHUANG HX, SNYDER CK, PU SF, ISHII DN: Insulin-like growth factors reverse or arrest diabetic neuropathy: effects on hyperalgesia and impaired nerve regeneration in rats. Exp. Neurol. (1996) 140(2):198-205.
32. SENGER DR, GALLI SJ, DVORAK AM et al.: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 219(4587):983-985.
33. SONDELL M, LUNDBORG G, KANJE M: Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J. Neurosci. (1999) 19(14):5731-5740.
34. SONDELL M, SUNDLER F, KANJE M: Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor. Eur. J. Neurosci. (2000) 12(12):4243-4254.
35. JIN KL, MAO XO, GREENBERG DA: Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc. Natl. Acad. Sci. USA (2000) 97(18):10242-10247.
36. MATSUZAKI H, TAMATANI M, YAMAGUCHI A et al.: Vascular endothelial growth factor rescues hippocampal neurons from glutamate-induced toxicity: signal transduction cascades. FASEB J. (2001) 15(7):1218-1220.
37. YANG ZJ, BAO WL, QIU MH et al.: Role of vascular endothelial growth factor in neuronal DNA damage and repair in rat brain following a transient cerebral ischemia. J. Neurosci. Res. (2002) 70(2):140-149.
38. WIDENFALK J, LIPSON A, JUBRAN M et al.: Vascular endothelial growth factor improves functional outcome and decreases secondary degeneration in experimental spinal cord contusion injury. Neuroscience (2003) 120(4):951-960.
39. SCHRATZBERGER P, SCHRATZBERGER G, SILVER M et al.: Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat. Med. (2000) 6(4):405-413.
40. MIYAKE T, KUNG CK, GOLDWASSER E: Purification of human erythropoietin. J. Biol. Chem. (1977) 252(15):5558-5564.
41. STORKEBAUM E, LAMBRECHTS D, CARMELIET P: VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays (2004) 26(9):943-954.
42. KONISHI Y, CHUI DH, HIROSE H, KUNISHITA T, TABIRA T: Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res. (1993) 609(1-2):29-35.
43. SAKANAKA M, WEN TC, MATSUDA S et al.: In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc. Natl. Acad. Sci. USA (1998) 95(8):4635-4640.
44. BRINES ML, GHEZZI P, KEENAN S et al.: Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. USA (2000) 97(19):10526-10531.
45. GENC S, KURALAY F, GENC K et al.: Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production. Neurosci. Lett. (2001) 298(2):139-141.
46. DIGICAYLIOGLU M, GARDEN G, TIMBERLAKE S, FLETCHER L, LIPTON SA: Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. Proc. Natl. Acad. Sci. USA (2004) 101(26):9855-9860.
47. CAMPANA WM, MYERS RR: Exogenous erythropoietin protects against dorsal root ganglion apoptosis and pain following peripheral nerve injury. Eur. J. Neurosci. (2003) 18(6):1497-1506.
48. THOENEN H, SENDTNER M: Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat. Neurosci. (2002) 5(Suppl.):1046-1050.
49. APFEL SC: Neurotrophic factor therapy-prospects and problems. Clin. Chem. Lab. Med. (2001) 39(4):351-355. An excellent review of the issues surrounding translation of neurotrophic factors into treatments for human disease.
50. APFEL SC, SCHWARTZ S, ADOMATO BT et al.: Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. JAMA (2000) 284(17):2215-2221.
51. PODUSLO JF, CURRAN GL: Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res. Mol. Brain Res. (1996) 36(2):280-286.
52. PRADAT PF, FINIELS F, KENNEL P et al.: Partial prevention of cisplatin-induced neuropathy by electroporation-mediated nonviral gene transfer. Hum. Gene Ther. (2001) 12(4):367-375.
53. PRADAT PF, KENNEL P, NAIMI-SADAOUI S et al.: Viral and non-viral gene therapy partially prevents experimental cisplatin-induced neuropathy. Gene Ther. (2002) 9(19):1333-1337. A nice comparison of the effectiveness of viral and non-viral gene transfer to muscle in the treatment of neuropathy.
54. PRADAT PF, KENNEL P, NAIMI-SADAOUI S et al.: Continuous delivery of neurotrophin 3 by gene therapy has a neuroprotective effect in experimental models of diabetic and acrylamide neuropathies. Hum. Gene Ther. (2001) 12(18):2237-2249.
55. KATO N, NEMOTO K, NAKANISHI K et al.: Nonviral gene transfer of human hepatocyte growth factor improves streptozotocin-induced diabetic neuropathy in rats. Diabetes (2005) 54(3):846-854.
56. FINK DJ, DELUCA NA, GOINS WF, GLORIOSO JC: Gene transfer to neurons using herpes simplex virus-based vectors. Annu. Rev. Neurosci. (1996) 19:265-287.
57. GLORIOSO JC, FINK DJ: Herpes vector-mediated gene transfer in treatment of diseases of the nervous system. Annu. Rev. Microbiol. (2004) 58:253-271.
58. BATTERSON W, ROIZMAN B: Characterization of the herpes simplex virion-associated factor responsible for the induction of α genes. J. Virol. (1983) 46(2):371-377.
59. CAMPBELL ME, PALFREYMAN JW, PRESTON CM: Identification of herpes simplex virus DNA sequences which encode a trans-acting polypeptide responsible for stimulation of immediate early transcription. J. Mol. Biol. (1984) 180(1):1-19.
60. MACKEM S, ROIZMAN B: Structural features of the herpes simplex virus alpha gene 4, 0, and 27 promoter-regulatory sequences which confer alpha regulation on chimeric thymidine kinase genes. J. Virol. (1982) 44(3):939-949.
61. PRESTON CM, FRAME MC, CAMPBELL ME: A complex formed between cell components and an HSV structural polypeptide binds to a viral immediate early gene regulatory DNA sequence. Cell (1988) 52(3):425-434.
62. KRISTIE TM, ROIZMAN B: Host cell protein bind to the cis-acting site required for virion-mediated induction of herpes simplex virus 1 α genes. Proc. Natl. Acad. Sci. USA (1987) 84:71-75.
63. WERSTUCK GH, CAPONE JP: An unusual cellular factor potentiates protein-DNA complex assembly Oct-1 and Vmw65. J. Biol. Chem. (1993) 268(2):1272-1278.
64. WILSON AC, LAMARCO K, PETERSON MG, HERR W: The VP16 accessory protein HCF is a family of polypeptides processed from a large precursor protein. Cell (1993) 74(1):115-125.
65. KWONG AD, KRUPER JA, FRENKEL N: Herpes simplex virus virion host shutoff function. J. Virol. (1988) 62(3):912-921.
66. OROSKAR AA, READ GS: Control of mRNA stability by the virion host shutoff function of herpes simplex virus. J. Virol. (1989) 63(5):1897-1906.
67. ROIZMAN B, SEARS A: Herpes simplex viruses and their replication. In: Fields' Virology (3rd Edition). Fields BN, Knipe DM, Howley PM (Eds), Lippincott-Raven, Philadelphia, PA, USA (1996):2231-2295.
68. ROIZMAN B, SEARS AE: Herpes simplex viruses and their replication. In: The Human Herpesviruses. Roizman B, Lopez C, Whitley RJ (Eds), Raven Press, New York, USA (1993):11-68.
69. SPIVACK JG, FRASER NW: Detection of herpes simplex virus type 1 transcripts during latent infection in mice. J. Virol. (1987) 61(12):3841-3847.
70. SPIVACK JG, FRASER NW: Expression of herpes simplex virus type 1 latency-associated transcripts in trigeminal ganglia of mice during acute infection and reactivation of latent infection. J. Virol. (1988) 62(5):1479-1485.
71. DESHMANE SL, FRASER NW: During latency, herpes simplex virus type 1 DNA is associated with nucleosomes in a chromatin structure. J. Virol. (1989) 63(2):943-947.
72. DRESSLER GR, ROCK DL, FRASER NW: Latent herpes simplex virus type 1 DNA is not extensively methylated in vivo. J. Gen. Virol. (1987) 68(Pt 6):1761-1765.
73. MELLERICK DM, FRASER NW: Physical state of the latent herpes simplex virus genome in a mouse model system: evidence suggesting an episomal state. Virology (1987) 158(2):265-275.
74. ROCK DL, FRASER NW: Latent herpes simplex virus type 1 DNA contains two copies of the virion DNA joint region. J. Virol. (1985) 55(3):849-852.
75. FINK DJ, DELUCA NA, YAMADA M, WOLFE DP, GLORIOSO JC: Design and application of HSV vectors for neuroprotection. Gene Ther. (2000) 7(2):115-119.
76. WOLFE D, GOINS WF, YAMADA M et al.: Engineering herpes simplex virus vectors for CNS applications. Exp. Neurol. (1999) 159(1):34-46.
77. KRISKY DM, WOLFE D, GOINS WF et al.: Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther. (1998) 5(12):1593-1603.
78. CHATTOPADHYAY M, WOLFE D, HUANG S et al.: In vivo gene therapy for pyridoxine-induced neuropathy by herpes simplex virus-mediated gene transfer of neurotrophin-3. Ann. Neurol. (2002) 51(1):19-27. The first demonstration of HSV-mediated gene transfer to DRG for the treatment of neuropathy.
79. CHATTOPADHYAY M, GOSS J, WOLFE D et al.: Protective effect of herpes simplex virus-mediated neurotrophin gene transfer in cisplatin neuropathy. Brain (2004) 127(Pt 4):929-939.
80. KIRCHMAIR R, WALTER DH, II M et al.: Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth. Circulation (2005) 111(20):2662-2670.
81. GOSS JR, GOINS WF, LACOMIS D et al.: Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neruropathy in streptozotocin-induced diabetes in the mouse. Diabetes (2002) 51(7):2227-2232.
82. CHATTOPADHYAY M, KRISKY D, WOLFE D et al.: HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy. Gene Ther. (2005) 12(18):1377-1384.
83. MCGEOCH DJ, DOLAN A, DONALD S, RIXON FJ: Sequence determination and genetic content of the short unique region in the genome of herpes simplex virus type 1. J. Mol. Biol. (1985) 181(1):1-13.
84. GOINS WF, STERNBERG LR, CROEN KD et al.: A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats. J. Virol. (1994) 68(4):2239-2252.
85. GOINS WF, LEE KA, CAVALCOLI JD et al.: Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity. J. Virol. (1999) 73(1):519-532.
86. LOKENSGARD JR, BERTHOMME H, FELDMAN LT: The latency-associated promoter of herpes simplex virus type 1 requires a region downstream of the transcription start site for long-term expression during latency. J. Virol. (1997) 71(9):6714-6719.
87. PALMER JA, BRANSTON RH, LILLEY CE et al.: Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system. J. Virol. (2000) 74(12):5604-5618.
88. LILLEY CE, GROUTSI F, HAN Z et al.: Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo. J. Virol. (2001) 75(9):4343-4356.
89. PEREZ MC, HUNT SP, COFFIN RS, PALMER JA: Comparative analysis of genomic HSV vectors for gene delivery to motor neurons following peripheral inoculation in vivo. Gene Ther. (2004) 11(13):1023-1032.
90. CHATTOPADHYAY M, WOLFE D, MATA M et al.: Long-term neuroprotection achieved with latency-associated promoter-driven herpes simplex virus gene transfer to the peripheral nervous system. Mol. Ther. (2005) 12(2):307-313. This study shows that with an appropriate choice of promoter element, therapeutic effects may be achieved 6 months after gene transfer by prolonged gene expression.
91. ISNER JM, ROPPER A, HIRST K: VEGF gene transfer for diabetic neuropathy. Hum. Gene Ther. (2001) 12(12):1593-1594. A description of the first human trial of gene transfer for the treatment of neuropathy.
92. SAHENK Z, NAGARAJA HN, MCCRACKEN BS et al.: NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology (2005) 65(5):681-689. The first report of treatment of an inherited neuropathy in patients with NT gene transfer.